Regen Biopharma, Inc.

As of June 30, 2026, Regen Biopharma, Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -15.17, indicating conservative leverage, while an interest coverage ratio of -3.81 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -489.72, reflecting losses generated across the asset base. The company generates approximately 236,561.00 in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Regen Biopharma, Inc.'s stock has declined approximately 96.04% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -803,860.00, while operating income came in at -803,859.00.

As of June 30, 2026, Regen Biopharma, Inc. holds 239.00 in cash and equivalents against 891,757.00 in total debt, resulting in a net debt position of 891,518.00. Total book value stands at -5.89M, with working capital of -5.88M providing operational flexibility.

Regen Biopharma, Inc. produced -445,249.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -339.81 and net profit margin of -501.43 provide insight into operational efficiency.

Regen Biopharma, Inc.'s most recent stock split took place on February 10, 2026 with a 1:2 split ratio.